SG11201809843SA - Phenolic compound and combination thereof with a benzodiazepin fused to 1,4-dihidropyridine for the treatment of central nervous and vascular systems affections - Google Patents
Phenolic compound and combination thereof with a benzodiazepin fused to 1,4-dihidropyridine for the treatment of central nervous and vascular systems affectionsInfo
- Publication number
- SG11201809843SA SG11201809843SA SG11201809843SA SG11201809843SA SG11201809843SA SG 11201809843S A SG11201809843S A SG 11201809843SA SG 11201809843S A SG11201809843S A SG 11201809843SA SG 11201809843S A SG11201809843S A SG 11201809843SA SG 11201809843S A SG11201809843S A SG 11201809843SA
- Authority
- SG
- Singapore
- Prior art keywords
- fused
- treatment
- central nervous
- dihidropyridine
- affections
- Prior art date
Links
- 150000002989 phenols Chemical class 0.000 title abstract 4
- 230000002792 vascular Effects 0.000 title abstract 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 polyphenol compounds Chemical class 0.000 abstract 2
- 235000013824 polyphenols Nutrition 0.000 abstract 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 abstract 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 230000001910 anti-glutamatergic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 150000001557 benzodiazepines Chemical class 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000003371 gabaergic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000059A CU24576B1 (es) | 2016-05-04 | 2016-05-04 | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
| PCT/CU2017/050003 WO2017190714A1 (es) | 2016-05-04 | 2017-05-03 | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809843SA true SG11201809843SA (en) | 2018-12-28 |
Family
ID=60202803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809843SA SG11201809843SA (en) | 2016-05-04 | 2017-05-03 | Phenolic compound and combination thereof with a benzodiazepin fused to 1,4-dihidropyridine for the treatment of central nervous and vascular systems affections |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10722491B2 (enExample) |
| EP (1) | EP3453704B1 (enExample) |
| JP (1) | JP6997995B2 (enExample) |
| KR (1) | KR102416478B1 (enExample) |
| CN (1) | CN109476627B (enExample) |
| AR (1) | AR108370A1 (enExample) |
| AU (1) | AU2017259749C1 (enExample) |
| BR (1) | BR112018072579B1 (enExample) |
| CA (1) | CA3023073C (enExample) |
| CL (1) | CL2018003114A1 (enExample) |
| CO (1) | CO2018011927A2 (enExample) |
| CU (1) | CU24576B1 (enExample) |
| EA (1) | EA037951B1 (enExample) |
| ES (1) | ES2878579T3 (enExample) |
| MX (1) | MX384967B (enExample) |
| PH (1) | PH12018502327A1 (enExample) |
| SG (1) | SG11201809843SA (enExample) |
| WO (1) | WO2017190714A1 (enExample) |
| ZA (1) | ZA201808161B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20160058A7 (es) | 2016-05-04 | 2017-12-08 | Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular |
| JP2022504852A (ja) * | 2018-10-16 | 2022-01-13 | サバン ベンチャーズ プロプライアタリー リミテッド | 医療機器の洗浄のための装置および方法 |
| EP4082548A2 (en) * | 2019-12-26 | 2022-11-02 | Centro de Investigación y Desarrollo de Medicamentos CIDEM | Use of a benzodiazepine derivative and method of treatment of traumatic brain injury |
| CU20190114A7 (es) | 2019-12-26 | 2021-08-06 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281714A (en) | 1990-08-16 | 1994-01-25 | American Home Products Corporation | N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase |
| MX9204939A (es) | 1991-09-06 | 1993-03-01 | American Home Prod | Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa. |
| ATE122671T1 (de) | 1992-07-17 | 1995-06-15 | Biogal Gyogyszergyar | Verfahren zur herstellung von 1,3-dioxan-4,6- dionderivaten. |
| JPH11180975A (ja) | 1997-10-13 | 1999-07-06 | Chemiprokasei Kaisha Ltd | アミノメチレンジオキサン誘導体、その製造方法および用途 |
| EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP2007063444A (ja) * | 2005-08-31 | 2007-03-15 | Tdk Corp | 錯化合物及びこれを用いた光記録媒体 |
-
2016
- 2016-05-04 CU CU2016000059A patent/CU24576B1/es unknown
-
2017
- 2017-05-03 WO PCT/CU2017/050003 patent/WO2017190714A1/es not_active Ceased
- 2017-05-03 CN CN201780040492.9A patent/CN109476627B/zh not_active Expired - Fee Related
- 2017-05-03 US US16/098,683 patent/US10722491B2/en not_active Expired - Fee Related
- 2017-05-03 EA EA201892462A patent/EA037951B1/ru unknown
- 2017-05-03 JP JP2019510749A patent/JP6997995B2/ja not_active Expired - Fee Related
- 2017-05-03 KR KR1020187035042A patent/KR102416478B1/ko not_active Expired - Fee Related
- 2017-05-03 ES ES17732730T patent/ES2878579T3/es active Active
- 2017-05-03 BR BR112018072579-0A patent/BR112018072579B1/pt not_active IP Right Cessation
- 2017-05-03 AU AU2017259749A patent/AU2017259749C1/en not_active Ceased
- 2017-05-03 SG SG11201809843SA patent/SG11201809843SA/en unknown
- 2017-05-03 CA CA3023073A patent/CA3023073C/en active Active
- 2017-05-03 EP EP17732730.1A patent/EP3453704B1/en active Active
- 2017-05-03 MX MX2018013422A patent/MX384967B/es unknown
- 2017-05-04 AR ARP170101153A patent/AR108370A1/es unknown
-
2018
- 2018-10-31 CL CL2018003114A patent/CL2018003114A1/es unknown
- 2018-11-02 CO CONC2018/0011927A patent/CO2018011927A2/es unknown
- 2018-11-05 PH PH12018502327A patent/PH12018502327A1/en unknown
- 2018-12-03 ZA ZA2018/08161A patent/ZA201808161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU24576B1 (es) | 2022-02-04 |
| JP2019516791A (ja) | 2019-06-20 |
| KR20210025138A (ko) | 2021-03-09 |
| AU2017259749A1 (en) | 2018-12-20 |
| EA037951B1 (ru) | 2021-06-11 |
| CL2018003114A1 (es) | 2019-06-14 |
| CA3023073C (en) | 2022-08-30 |
| EA201892462A1 (ru) | 2019-07-31 |
| EP3453704A1 (en) | 2019-03-13 |
| CO2018011927A2 (es) | 2019-02-08 |
| US10722491B2 (en) | 2020-07-28 |
| ES2878579T3 (es) | 2021-11-19 |
| BR112018072579B1 (pt) | 2024-02-20 |
| CU20160059A7 (es) | 2017-12-08 |
| AU2017259749B2 (en) | 2021-08-19 |
| MX384967B (es) | 2025-03-14 |
| WO2017190714A1 (es) | 2017-11-09 |
| MX2018013422A (es) | 2019-08-16 |
| CN109476627B (zh) | 2021-06-15 |
| JP6997995B2 (ja) | 2022-02-04 |
| BR112018072579A2 (pt) | 2019-02-19 |
| AR108370A1 (es) | 2018-08-15 |
| CN109476627A (zh) | 2019-03-15 |
| PH12018502327A1 (en) | 2019-09-02 |
| CA3023073A1 (en) | 2017-11-09 |
| EP3453704B1 (en) | 2021-06-16 |
| ZA201808161B (en) | 2021-10-27 |
| AU2017259749C1 (en) | 2021-12-02 |
| US20190133996A1 (en) | 2019-05-09 |
| KR102416478B1 (ko) | 2022-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502327A1 (en) | Phenolic compound and combination thereof with a benzodiazepin melted to 1,4-dihydropyridine for the treatment of central and vascular nervous system affections | |
| MX2021011438A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. | |
| PH12019501254A1 (en) | Small molecule inhibitors of the jak family of kinases | |
| SA517390509B1 (ar) | مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه | |
| GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| AU2017264697A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
| WO2011041989A3 (es) | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular | |
| HK1212684A1 (zh) | 三環喹啉和喹喔啉衍生物 | |
| MX366623B (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| WO2017027810A3 (en) | Compositions and methods that promote the hypoxia response for treatment of mitochondrial dysfunction and oxidative stress disorders | |
| TN2017000376A1 (en) | Bicyclic ketone sulfonamide compounds | |
| MX368956B (es) | Derivados de 4-azaindol. | |
| CO6721049A2 (es) | Derivados de 5,6-dihiro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de beta secretasa (bace) | |
| JOP20200041A1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| WO2018086585A8 (zh) | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 | |
| PH12017500170B1 (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| UA120083C2 (uk) | АНТИМЕТАСТАТИЧНІ 2H-СЕЛЕНОФЕНО[3,2-h]ХРОМЕНИ, ЇХ СИНТЕЗ ТА СПОСОБИ ЗАСТОСУВАННЯ ЦИХ АГЕНТІВ | |
| NZ760781A (en) | Process for the preparation of standardized composition of arjunoglucoside from the bark of terminalia arjuna | |
| CU20160142A7 (es) | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4 dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular | |
| CL2018003113A1 (es) | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular. | |
| GB201312819D0 (en) | Novel compounds | |
| WO2018203664A8 (ko) | sRAGE를 분비하는 줄기세포를 포함하는 신경질환 또는 심혈관 질환의 예방 또는 치료용 약학 조성물 | |
| SG11201706076QA (en) | Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same |